These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26879687)

  • 1. STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies.
    Tomlinson L; Ramaiah L; Tripathi NK; Barlow VG; Vitsky A; Poitout-Belissent FM; Bounous DI; Ennulat D
    Toxicol Pathol; 2016 Feb; 44(2):163-72. PubMed ID: 26879687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies.
    Keirstead ND; Janovitz EB; Meehan JT; LeRoy BE; Megill JR; Peterson RA; Masson RG; Marxfeld HA
    Toxicol Pathol; 2019 Jun; 47(4):461-468. PubMed ID: 31018785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Society of Toxicologic Pathology position paper on best practices on recovery studies: the role of the anatomic pathologist.
    Perry R; Farris G; Bienvenu JG; Dean C; Foley G; Mahrt C; Short B;
    Toxicol Pathol; 2013; 41(8):1159-69. PubMed ID: 23531793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STP position paper: interpreting the significance of increased alveolar macrophages in rodents following inhalation of pharmaceutical materials.
    Nikula KJ; McCartney JE; McGovern T; Miller GK; Odin M; Pino MV; Reed MD
    Toxicol Pathol; 2014; 42(3):472-86. PubMed ID: 24178583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the evaluation of pathology data in nonclinical safety biomarker qualification studies.
    Burkhardt JE; Pandher K; Solter PF; Troth SP; Boyce RW; Zabka TS; Ennulat D
    Toxicol Pathol; 2011 Dec; 39(7):1129-37. PubMed ID: 22116771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Principles for Assessing Adversity in Toxicologic Clinical Pathology.
    Ramaiah L; Tomlinson L; Tripathi NK; Cregar LC; Vitsky A; Beust BV; Barlow VG; Reagan WJ; Ennulat D
    Toxicol Pathol; 2017 Feb; 45(2):260-266. PubMed ID: 28056663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scientific and Regulatory Policy Committee Points to Consider Review: Inclusion of Reproductive and Pathology End Points for Assessment of Reproductive and Developmental Toxicity in Pharmaceutical Drug Development.
    Halpern WG; Ameri M; Bowman CJ; Elwell MR; Mirsky ML; Oliver J; Regan KS; Remick AK; Sutherland VL; Thompson KE; Tremblay C; Yoshida M; Tomlinson L
    Toxicol Pathol; 2016 Aug; 44(6):789-809. PubMed ID: 27235322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Study Design Variables on Clinical Pathology Data.
    Aulbach A; Provencher A; Tripathi N
    Toxicol Pathol; 2017 Feb; 45(2):288-295. PubMed ID: 28178900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper.
    Tomohiro M; Okabe T; Kimura Y; Kinoshita K; Maeda M; Mitobe Y; Motoyama K; Yonezawa R; Sasaki S; Fujiwara M; Watanabe K
    Toxicol Pathol; 2019 Feb; 47(2):108-120. PubMed ID: 30636562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Society of toxicologic pathology position paper: review series: assessment of circulating hormones in nonclinical toxicity studies: general concepts and considerations.
    Stanislaus D; Andersson H; Chapin R; Creasy D; Ferguson D; Gilbert M; Rosol TJ; Boyce RW; Wood CE
    Toxicol Pathol; 2012 Aug; 40(6):943-50. PubMed ID: 22569585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pathology testing recommendations for nonclinical toxicity and safety studies. AACC-DACC/ASVCP Joint Task Force.
    Weingand K; Bloom J; Carakostas M; Hall R; Helfrich M; Latimer K; Levine B; Neptun D; Rebar A; Stitzel K
    Toxicol Pathol; 1992; 20(3 Pt 2):539-43. PubMed ID: 1296288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scientific and Regulatory Policy Committee: Recommended ("Best") Practices for Determining, Communicating, and Using Adverse Effect Data from Nonclinical Studies.
    Kerlin R; Bolon B; Burkhardt J; Francke S; Greaves P; Meador V; Popp J
    Toxicol Pathol; 2016 Feb; 44(2):147-62. PubMed ID: 26704930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harmonization of animal clinical pathology testing in toxicity and safety studies. The Joint Scientific Committee for International Harmonization of Clinical Pathology Testing.
    Weingand K; Brown G; Hall R; Davies D; Gossett K; Neptun D; Waner T; Matsuzawa T; Salemink P; Froelke W; Provost JP; Dal Negro G; Batchelor J; Nomura M; Groetsch H; Boink A; Kimball J; Woodman D; York M; Fabianson-Johnson E; Lupart M; Melloni E
    Fundam Appl Toxicol; 1996 Feb; 29(2):198-201. PubMed ID: 8742316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Best practices for clinical pathology testing in carcinogenicity studies.
    Young JK; Hall RL; O'Brien P; Strauss V; Vahle JL
    Toxicol Pathol; 2011 Feb; 39(2):429-34. PubMed ID: 21297067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STP position paper: Recommended practices for sampling and processing the nervous system (brain, spinal cord, nerve, and eye) during nonclinical general toxicity studies.
    Bolon B; Garman RH; Pardo ID; Jensen K; Sills RC; Roulois A; Radovsky A; Bradley A; Andrews-Jones L; Butt M; Gumprecht L
    Toxicol Pathol; 2013; 41(7):1028-48. PubMed ID: 23475559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of clinical pathology data: correlating changes with other study data.
    Everds NE
    Toxicol Pathol; 2015 Jan; 43(1):90-7. PubMed ID: 25361750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STP position paper: best practice guideline for the routine pathology evaluation of the immune system.
    Haley P; Perry R; Ennulat D; Frame S; Johnson C; Lapointe JM; Nyska A; Snyder P; Walker D; Walter G;
    Toxicol Pathol; 2005; 33(3):404-7; discussion 408. PubMed ID: 15805080
    [No Abstract]   [Full Text] [Related]  

  • 18. Best practices for veterinary toxicologic clinical pathology, with emphasis on the pharmaceutical and biotechnology industries.
    Tomlinson L; Boone LI; Ramaiah L; Penraat KA; von Beust BR; Ameri M; Poitout-Belissent FM; Weingand K; Workman HC; Aulbach AD; Meyer DJ; Brown DE; MacNeill AL; Bolliger AP; Bounous DI
    Vet Clin Pathol; 2013 Sep; 42(3):252-69. PubMed ID: 23889060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appropriate use of recovery groups in nonclinical toxicity studies: value in a science-driven case-by-case approach.
    Pandher K; Leach MW; Burns-Naas LA
    Vet Pathol; 2012 Mar; 49(2):357-61. PubMed ID: 21810619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicologic Pathology Forum*: Opinion on Sexual Maturity and Fertility Assessment in Long-tailed Macaques ( Macaca fascicularis) in Nonclinical Safety Studies.
    Mecklenburg L; Luetjens CM; Weinbauer GF
    Toxicol Pathol; 2019 Jun; 47(4):444-460. PubMed ID: 30898082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.